BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31471587)

  • 1. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.
    He R; Devine DJ; Tu ZJ; Mai M; Chen D; Nguyen PL; Oliveira JL; Hoyer JD; Reichard KK; Ollila PL; Al-Kali A; Tefferi A; Begna KH; Patnaik MM; Alkhateeb H; Viswanatha DS
    Mod Pathol; 2020 Mar; 33(3):334-343. PubMed ID: 31471587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication.
    Kim JJ; Lee KS; Lee TG; Lee S; Shin S; Lee ST
    Diagn Pathol; 2022 Jan; 17(1):14. PubMed ID: 35081962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data.
    Spencer DH; Abel HJ; Lockwood CM; Payton JE; Szankasi P; Kelley TW; Kulkarni S; Pfeifer JD; Duncavage EJ
    J Mol Diagn; 2013 Jan; 15(1):81-93. PubMed ID: 23159595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
    Au CH; Wa A; Ho DN; Chan TL; Ma ES
    Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate Detection and Quantification of FLT3 Internal Tandem Duplications in Clinical Hybrid Capture Next-Generation Sequencing Data.
    Tung JK; Suarez CJ; Chiang T; Zehnder JL; Stehr H
    J Mol Diagn; 2021 Oct; 23(10):1404-1413. PubMed ID: 34363960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection the Frequency and Characteristics of FLT3 Internal Tandem Duplication Mutations by Capillary Electrophoresis Assay and Next-Generation Sequencing in.
    Ma L; Cao Y; Jiang Y; Cong X; Lu S; Shen J; Liu Q; Han C; Zhan Y; Cao Y
    Clin Lab; 2016 Oct; 62(10):2065-2072. PubMed ID: 28164543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technological Advances:
    Akabari R; Qin D; Hussaini M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive review and evaluation of computational methods for identifying FLT3-internal tandem duplication in acute myeloid leukaemia.
    Yuan D; He X; Han X; Yang C; Liu F; Zhang S; Luan H; Li R; He J; Duan X; Wang D; Zhou Q; Gao S; Niu B
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33851200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application.
    Lee S; Sun CH; Jang H; Kim D; Yoon SS; Koh Y; Na SC; Cho SI; Kim MJ; Seong MW; Byun JM; Yun H
    BMC Bioinformatics; 2023 Feb; 24(1):62. PubMed ID: 36823555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia.
    Liu SB; Qiu QC; Bao XB; Ma X; Li HZ; Liu YJ; Chen SN; Song YH; Wu DP; Xue SL
    Cancer Sci; 2018 Dec; 109(12):3981-3992. PubMed ID: 30320942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of High-throughput Sequencing in Acute Myeloid Leukemia Patients with Positive FLT3-ITD].
    Ma L; Jiang YW; Wang ST; Liu Q; Cong X; Shen J; Cao YY; Cao YT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):381-7. PubMed ID: 27150996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia.
    Zhang Y; Zhang Y; Wang F; Wang M; Liu H; Chen X; Cao P; Ma X; Teng W; Zhang X; Liu H
    Cancer Gene Ther; 2020 Feb; 27(1-2):81-88. PubMed ID: 31285539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.
    He R; Devine DJ; Tu ZJ; Mai M; Chen D; Nguyen PL; Oliveira JL; Hoyer JD; Reichard KK; Ollila PL; Al-Kali A; Tefferi A; Begna KH; Patnaik MM; Alkhateeb H; Viswanatha DS
    Mod Pathol; 2020 Mar; 33(3):514. PubMed ID: 31591496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
    Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q
    Gene; 2020 Feb; 726():144195. PubMed ID: 31669649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
    Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
    Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.
    Schwartz GW; Manning B; Zhou Y; Velu P; Bigdeli A; Astles R; Lehman AW; Morrissette JJD; Perl AE; Li M; Carroll M; Faryabi RB
    Clin Cancer Res; 2019 Jan; 25(2):573-583. PubMed ID: 30181385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms.
    Tsai HK; Brackett DG; Szeto D; Frazier R; MacLeay A; Davineni P; Manning DK; Garcia E; Lindeman NI; Le LP; Lennerz JK; Gibson CJ; Lindsley RC; Kim AS; Nardi V
    J Mol Diagn; 2020 Sep; 22(9):1162-1178. PubMed ID: 32603763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
    Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
    Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.